Lineage Cell Therapeutics, Inc.
LCTX· NYSE
LCTXLineage Cell Therapeutics, Inc.
Filed Mar 10, 2025 · 10-K · 69 days after period end · 0000950170-25-036309
derived · Computed from the longer spans the company filed.
| Metric | Q4 2024dderived from reported figures | Q4 2023 | Q4 2022 | Q4 2021 |
|---|---|---|---|---|
| Revenue | $2.87M | $2.09M | $1.92M | $1.17M |
| Net Income | -$3.27M | -$4.78M | -$6.35M | -$28.99M |
| EPS Diluted | — | -$0.03 | -$0.03 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
ended Dec 31, 2024 · filed Mar 10, 2025 · 69 d after period end
